This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Ocular Drug Delivery System Market

Market Insights on Ocular Drug Delivery System covering sales outlook, demand forecast & up-to-date key trends

Ocular Drug Delivery System Market by Technology (Implantable Ocular Drug Delivery Systems, Particulate Drug Delivery Systems), Dosage Form (Ophthalmic Solution, Ophthalmic Suspension, Ophthalmic Emulsion), Distribution Channel & Region - Forecast to 2021-2031

Ocular Drug Delivery System Market Snapshot

[250 Pages Report] The Ocular Drug Delivery System Market is forecast to surpass US$ 14.47 Bn in 2021, according to Future Market Insights (FMI). As a result of rising cases of ophthalmic diseases, focus on advanced treatment is rising, enabling surge in ocular drug delivery systems demand at a CAGR of 6.8 % between 2020 and 2031.

As per FMI analysis, global ocular drug delivery systems sales will total US$ 27.82 Bn by 2031. The demand for particulate drug delivery systems will be highest among all. It is expected to account for over 68% of the global market in 2021.

Customize this Report

Let us know your requirement to get
100% FREE customization

Key Points Covered in Ocular Drug Delivery System Market Study

  • Ocular Drug Delivery System Market estimates and forecast 2016-2031
  • Key drivers and restraints impacting market growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Brand share and Market Share Analysis
  • Key Product Innovations and Regulatory Climate
  • COVID-19 Impact on Ocular drug delivery system Market and How to Navigate
  • Recommendation on Key Winning Strategies

2016-2020 Ocular Drug Delivery System Market Outlook Compared to 2021-2031 Forecast

According to Future Market Insights (FMI), the sales of ocular drug delivery system have grown at an 6.8% CAGR between 2016 and 2020. Ocular drug delivery systems are platforms designed for dispensing drug, biologic, biopharmaceutical, and botanical therapeutics for treating macular degeneration, glaucoma, presbyopia, allergy, anti-viral, dry eye, anti-infective and anti-inflammatory indications.

To overcome ocular drug delivery barriers and improve bioavailability, various conventional and novel drug delivery systems have been developed such as ointments, emulsion, suspensions, aqueous gels, nanomicelles, liposomes, dendrimers, implants, contact lenses, nanoparticles, Nano suspensions, microneedles, and in situ thermosensitive gels for the earlier mention ocular diseases.

The research focus on key market players is on developing tools to improve the efficacy of spatiotemporal drug administration. For instance, in May 2017, pSivida Corp. announced positive 12-month follow-up data of phase 3 trials for its Durasert, a three-year uveitis implant, improving the treatment of posterior uneitis infection.

Research studies on novel drug delivery treatments for posterior eye therapy by using implantable devices and micro- and nanoparticles are expected to increase the efficacy of advanced ocular drug delivery technologies.

Companies specializing in ocular drug delivery technologies are increasing their research and development expenditure constantly. This trend is likely to continue during the forecast period. For instance, in 2016, Valeant Pharmaceuticals International, Inc. invested US$ 421.0 Mn in research and development to develop platforms for ocular drug delivery technologies.

Huge expenditure is required during developmental stages of advanced ocular drug delivery technologies. With the rise in the number of new entrants, the overall research and development expenses are projected to rise exponentially, along with collaborations and licensing agreements with several research institutes.

With pharmaceutical spending consistently rising in developed countries, the demand for ocular drug delivery system is expected to increase.

Emerging markets, especially large markets such as India and China, have significant untapped potential. With rise in disposable income, these nations are continuing to spend on innovative technologies for better treatment modalities.

Future Market Insights projects the global ocular drug delivery system market to rise at 6.8 % CAGR between 2021 and 2031.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How are Low Bioavailability of Drugs Affecting the Ocular Drug Delivery System Market?

The low bioavailability of active drug ingredient administered in eye by conventional topical routes such as solutions & ointments is usually a major obstacle to overcome. This is a result of effective multiple physiological barriers for drug entry. The administration of drugs to the posterior segment of the ocular tissue is inhibited by the same factors that account for the poor ocular bioavailability.

To enhance the bioavailability of ocular therapeutics, there are substantial efforts directed towards advanced drug delivery technologies for ophthalmic administration.

Studies exhibit that micellar formulations can improve the bioavailability of the drugs in ocular tissues, suggesting enhanced therapeutic outcomes. Also, derivatizing active pharmaceutical ingredients (API) and enhancing the ocular drug bioavailability using an emulsion as a carrier system is a phenomenal concept followed by key players in this space.

To increase drug penetration through corneal & other ocular barriers in the anterior portion of the eye, key players are focusing on the development of new drug delivery techniques in the ophthalmic market.

What are the Opportunities for Ocular Drug Delivery System Market Growth?

In case of advanced ocular drug delivery systems, insertion techniques are difficult and expulsion of shields occurs, causing the occasional inadvertent loss of the drug. Thus, using penetration enhancers to improve the corneal drug transport.

Use of ocular penetration enhancers like para-cellular pathways and phase transitions systems are likely  increase the opportunity for ocular drug delivery system market. Moreover, the protective barrier mechanisms of the human eye arrest the efficiency of drug delivery, providing an opportunity in developing mechanisms to bypass these barriers during drug administration.

Several ongoing clinical trials are executed to understand the efficacy of bypass mechanisms, which is predicted to efficiently address the problem of ocular drug bio-availability.

In June 2016, EyeGate Pharmaceuticals, Inc. announced the interim data of Phase 1b/2a trial of the iontophoretic EGP-437 which demonstrated a safety clinical profile with efficient bypass mechanisms. Such consistent research initiatives undertaken by leading players will bode well for the market.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

What are the Factors Restraining Ocular Drug Delivery System Demand?

Ocular inserts and implants provide advantages such as high corneal penetration, greater dissolution area, and sustained release of medication.

However, the foreign body sensation in the eye due to the solidity of the implants lead to discomfort accompanied by irritation, drug dilution, and excessive lachrymation.

Moreover, nasolacrimal drainage through lacrimal canaliculi refers to the systemic absorption of the drug across the gastrointestinal tract or the nasal mucosa, which leads to loss in its overall volume. This reduction in the volume of drug and rare cases of allergic reactions in the lacrimal system after the drug passage are some of the factors restraining the efficiency of ocular drug delivery.

Additionally, the reduction in patient compliance as well as adherence to novel ocular therapies due to high cost and associated complexities are anticipated to act as barriers for advanced drug delivery technologies in the global ocular drug delivery technologies market.

What Is the Impact of the COVID-19 Crisis on Ocular drug delivery system Market?

COVID-19 pandemic is expected to hamper growth prospects for the ocular drug delivery system market. Significant reduction in the physicians’ office visits and subsequent decline in number of prescription and OTC eye drop purchase is expected to hamper the market growth during COVID-19.

However, nationwide COVID-19 vaccine availability and speedy vaccination programs are expected to help the market set on path of recovery in the coming 1-2 years

New eye treatment product launches, branded as well as generic, are expected to hamper growth for a short-term. Besides this, disruption in the supply chain, delay in pipeline research and development, and changing priority of leading healthcare companies will pose challenges for the market.

Ocular Drug Delivery System Market - Country-wise Insights

How Lucrative is the Opportunity in the U.S?

The U.S. holds over 86% share in the ocular drug delivery system market in North America. In the U.S., growth is led by research collaboration and license agreement for clinical products. Rising technological advancements gives opportunity to manufacturers to deliver therapeutic drugs to targeted ocular tissues in sustained form, and provides protection from inflammatory conditions.

Moreover, expansion strategies are implemented by  some of the leading manufacturers in the country to strengthen their product portfolio. For instance, in October, 2020, Ocular Therapeutix™ and AffaMed Therapeutics announced license agreement and collaboration for DEXTENZA® and OTX-TIC in Asia.

What are the Factors Driving Revenue Generation in the U.K.?

The U.K. market will account for over 24% of the Europe market through the assessment period ending in 2031. Common clinical developments, the demand for extensive product portfolios, and improvements in drug development pipelines and production capacities are key factors speeding growth in the U.K. market.

Some of the market players are focusing on acquisition to expand their portfolio for over-the-counter drugs in the U.K. market. 

Ocular Drug Delivery System Market Download Report Brochure

What are the Key Factors Enabling Growth in Germany?

Germany market will exhibit a 4.6% CAGR throughout the forecast period. Regulatory guidelines are relatively strict in Germany. As a result, achieving drug approvals is hard process. Germany is the second leading market in Europe. Some of the leading players are eying to expand their footprint in Germany.

For instance, Vision Ophthalmology Group GmbH is acquired by AddLife AB, an independent operator in Life Science that offers high-quality products and services within a wide variety of therapeutic areas to both private and public sectors across Europe.

What are the Favorable Policies Driving Japan Market?

The Japan market will account for more than 52% of the sales registered in East Asia in 2021. Increasing healthcare spending has improved the quality of healthcare, while boosting the demand for pharmaceutical products in Japan.

According to International Trade Administration, the overall Japan market for  prescription as well as over-the-counter drugs totalled US$ 105 Bn in 2019. The government of Japan provides for healthcare spending of around 40% people living in the country via the national insurance schemes. These policies will continue favoring expansion of the market in Japan.

Japan’s pharmaceutical sector will showcase a moderate growth in the comig years due to high pricing. Despite this, it will remain a favourable destination for international biopharmaceutical companies for drug development and innovative therapies.

Ocular Drug Delivery System Market - Category-wise Insights

What is Nano-Particle Drug Delivery Systems Revenue by Technology?

Nano-Particle drug delivery systems has a higher potential for growth in the coming years. It is likely to exhibit a CAGR of 7.6% in the near future. Nanoparticles have been designed to overcome the barriers, increasing the drug penetration at the target site and prolonging the drug levels by few internals of drug administrations in lower doses without any toxicity compared to the conventional eye drops.

What is the Market Share of Ophthalmic Solution?

Ophthalmic solution will continue to dominate the market during the forecast period and it is expected to hold around 60% of the market share through the end of 2031.

What is the Scope for Growth of Mail Order Pharmacies?

While hospital pharmacies are currently leading the market, mail order pharmacies will exhibit high growth in the ocular drug delivery systems market at 8.9% CAGR in the forecast period. This will be primarily due to higher acceptance of online sales channel that provide discounts and offers, which reduces the overall costs of systems and medications.

Ocular Drug Delivery System Market - Competitive Landscape

Manufacturers in the ocular drug delivery system market are primarily aiming to carry out strategic collaborations and R&D to consolidate growth in a competitive and fragmented market.

For Instance, on March 31, 2017, Clear side Biomedical entered into a strategic collaboration with EyeKor to support Clearside’s clinical development efforts.

In September, 2020, Bausch Health Companies Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Alaway® Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100)

In January 2020, In February, 2021, Alimera Sciences continued Global geographic expansion with launch of ILUVIEN in Finland.

Ocular Drug Delivery System Market - Scope of the Report

Attribute

Details

Ocular Drug Delivery System Market - Forecast Period

2021-2031

Historical Data Available for

2016-2020

Ocular Drug Delivery System Market  - Analysis

USD Million for Value/ Units in Million for Volume

Ocular Drug Delivery System Market - Key Countries Covered

US, Canada, Germany, U.K., France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, South Africa

Ocular Drug Delivery System Market - Key Segments Covered

Technology,  Dosage Form, Distribution Channel, and Region

Ocular Drug Delivery System Market - Key Companies Profiled

  • Graybug Vision Inc.
  • Allergan Plc.
  • Ocular Therapeutix, Inc.
  • Alimera Sciences
  • pSivida,
  • Santen Pharmaceutical Co., Ltd
  • Taiwan Liposome Company Ltd.
  • Envisia Therapeutics
  • Eyegate Pharma
  • Valeant Pharmaceuticals International, Inc
  • Vision Ophthalmology Group GmbH
  • Clearside Biomedical
  • URSAPHARM Arzneimittel GmbH

Report Coverage

Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Ocular Drug Delivery Systems Market by Category

Technology:

  • Implantable Ocular Drug Delivery Systems
  • Particulate Drug Delivery Systems
  • Nano-Particle Drug Delivery System

Dosage Form:

  • Ophthalmic Solution
  • Ophthalmic Suspension
  • Ophthalmic Emulsion
  • Ophthalmic Gels
  • Ophthalmic Ointments

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • Mail Order Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

The ocular drug delivery systems market is forecast to surpass a valuation of US$ 27.82 Bn by 2031.

According to FMI’s analysis, the demand for ocular drug delivery systems consistently rose, at a CAGR of 5.1% between 2016 and 2020.

It is a prevalent trend among the market players to focus on development and modification of drug properties. Through this, they intend to improve drug permeation and drug bioavailability.

The ocular drug delivery systems market will continue gaining from the increasing adoption of patient compliant nanomedicine based therapeutic agents that offer improved efficacy for the treatment of anterior and posterior segment ocular disorders.

North America will remain dominant in the global market. At presents it holds around 51% of the overall ocular drug delivery systems market. Canada will emerge as the fastest growth market within North America, yet the U.S. is forecast to remain dominant through the assessment period.

The U.S., Canada, U.K., Germany, and Japan are the key markets of ocular drug delivery systems.

The top five players in ocular drug delivery systems market are Valeant Pharmaceuticals International, Inc, Santen Pharmaceutical Co., Ltd, Allergan, Plc, Alimera Sciences, and Vision Ophthalmology Group GmbH. These companies account for nearly 68% of the global market share.

As per FMI analysis, the Europe ocular drug delivery systems market is expected to rise at a CAGR of 6.6% between 2021 and 2031.

The Japan ocular drug delivery systems market is expected to exhibit growth at 6.1% CAGR during the forecast period. South Korea holds a revenue share of 0.4% in the global ocular drug delivery systems market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusion & Exclusion

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Market Background

    4.1. Macro-Economic Factors

        4.1.1. GDP Growth Outlook

        4.1.2. Global Healthcare Industry Outlook

        4.1.3. Increasing Per Capita Healthcare Spending

        4.1.4. Income Per Capita Outlook

    4.2. Forecast Factors - Relevance & Impact

        4.2.1. Product Availability

        4.2.2. Rising Demand of Non-Invasive Ocular Drug Delivery Techniques

        4.2.3. Global Ocular Drug Delivery Systems Market Statistics 

        4.2.4. Increase in Technological Advancement 

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunity Analysis

5. Market Context

    5.1. Key Product Features and Their USPs

    5.2. Product Adoption / Usage Analysis

    5.3. Key Promotional Strategies, By Manufacturers 

    5.4. Regulations, By Region

    5.5. Reimbursement Scenario

6. COVID19 Crisis Analysis

    6.1. Current Economic Projection as compared to 2008 financial analysis

    6.2. COVID19 and Impact Analysis

        6.2.1. Revenue by Product

        6.2.2. Revenue by Dosage Form

        6.2.3. Revenue by Distribution Channel

        6.2.4. Revenue by Country

    6.3. 2020 Market Scenario

7. Global Ocular Drug Delivery Systems Market Volume (Units) Analysis 2016-2020 and Forecast, 2021-2031

    7.1. Historical Market Volume (Units) Analysis, 2016-2020

    7.2. Current and Future Market Volume (Units) Projections, 2021-2031

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Ocular Drug Delivery Systems Market - Pricing Analysis

    8.1. Country Pricing Analysis by Technology

    8.2. Pricing Break-up

        8.2.1. Manufacturer Level Pricing

        8.2.2. Distributor Level Pricing

    8.3. Latin America and Middle East Average Pricing Analysis Benchmark

9. Global Ocular Drug Delivery Systems Market Value Analysis 2016-2020 and Forecast, 2021-2031

    9.1. Historical Market Value (US$ Mn) Analysis, 2016-2020

    9.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031

        9.2.1. Y-o-Y Growth Trend Analysis

        9.2.2. Absolute $ Opportunity Analysis

10. Global Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031, by Technology 

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis by Technology, 2016-2020

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Technology, 2021-2031

        10.3.1. Implantable Ocular Drug Delivery Systems

        10.3.2. Particulate Drug Delivery Systems 

        10.3.3. Nano-Particle drug Delivery systems

    10.4. Market Attractiveness Analysis by Technology

11. Global Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031, by Dosage Form 

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis by Dosage Form, 2016-2020

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Dosage Form, 2021-2031

        11.3.1. Ophthalmic Solution

        11.3.2. Ophthalmic Suspension

        11.3.3. Ophthalmic Emulsion

        11.3.4. Ophthalmic Gels

        11.3.5. Ophthalmic Ointments

    11.4. Market Attractiveness Analysis by Dosage Form

12. Global Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel 

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2016-2020

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021-2031

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies

        12.3.3. Drug Stores

        12.3.4. Mail Order Pharmacies

    12.4. Market Attractiveness Analysis by Distribution Channel

13. Global Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031, by Region

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Region, 2016-2020

    13.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021-2031

        13.3.1. North America

        13.3.2. Latin America

        13.3.3. Europe

        13.3.4. East Asia

        13.3.5. South Asia

        13.3.6. Oceania

        13.3.7. Middle East and Africa (MEA)

    13.4. Market Attractiveness Analysis By Region

14. North America Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020

    14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031

        14.3.1. By Country

            14.3.1.1. U.S.

            14.3.1.2. Canada

        14.3.2. By Technology

        14.3.3. By Dosage Form

        14.3.4. By Distribution Channel

    14.4. Market Attractiveness Analysis

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

15. Latin America Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020

    15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031

        15.3.1. By Country

            15.3.1.1. Brazil

            15.3.1.2. Mexico

            15.3.1.3. Argentina

            15.3.1.4. Rest of Latin America

        15.3.2. By Technology

        15.3.3. By Dosage Form

        15.3.4. By Distribution Channel

    15.4. Market Attractiveness Analysis

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

16. Europe Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020

    16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031

        16.3.1. By Country

            16.3.1.1. Germany

            16.3.1.2. Italy

            16.3.1.3. France

            16.3.1.4. U.K.

            16.3.1.5. Spain

            16.3.1.6. Russia

            16.3.1.7. Rest of Europe

        16.3.2. By Technology

        16.3.3. By Dosage Form

        16.3.4. By Distribution Channel

    16.4. Market Attractiveness Analysis

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

17. South Asia Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020

    17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031

        17.3.1. By Country

            17.3.1.1. India

            17.3.1.2. Thailand

            17.3.1.3. Indonesia

            17.3.1.4. Malaysia

            17.3.1.5. Rest of South Asia

        17.3.2. By Technology

        17.3.3. By Dosage Form

        17.3.4. By Distribution Channel

    17.4. Market Attractiveness Analysis

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

18. East Asia Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020

    18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031

        18.3.1. By Country

            18.3.1.1. China

            18.3.1.2. Japan

            18.3.1.3. South Korea

            18.3.1.4. Rest of East Asia

        18.3.2. By Technology

        18.3.3. By Dosage Form

        18.3.4. By Distribution Channel

    18.4. Market Attractiveness Analysis

    18.5. Key Market Participants - Intensity Mapping

    18.6. Drivers and Restraints - Impact Analysis

19. Oceania Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020

    19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031

        19.3.1. By Country

            19.3.1.1. Australia

            19.3.1.2. New Zealand

        19.3.2. By Technology

        19.3.3. By Dosage Form

        19.3.4. By Distribution Channel

    19.4. Market Attractiveness Analysis

    19.5. Key Market Participants - Intensity Mapping

    19.6. Drivers and Restraints - Impact Analysis

20. Middle East and Africa Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031

    20.1. Introduction

    20.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020

    20.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031

        20.3.1. By Country

            20.3.1.1. GCC Countries

            20.3.1.2. South Africa

            20.3.1.3. Rest of Middle East and Africa

        20.3.2. By Technology

        20.3.3. By Dosage Form

        20.3.4. By Distribution Channel

    20.4. Market Attractiveness Analysis

    20.5. Key Market Participants - Intensity Mapping

    20.6. Drivers and Restraints - Impact Analysis

21. Key and Emerging Countries Ocular Drug Delivery Systems Market Analysis 2016-2020 and Forecast 2021-2031

    21.1. Introduction

        21.1.1. Market Value Proportion Analysis, By Key Countries

        21.1.2. Global Vs. Country Growth Comparison

    21.2. U.S. Ocular Drug Delivery Systems Market Analysis

        21.2.1. By Technology

        21.2.2. By Dosage Form

        21.2.3. By Distribution Channel

    21.3. Canada Ocular Drug Delivery Systems Market Analysis

        21.3.1. By Technology

        21.3.2. By Dosage Form

        21.3.3. By Distribution Channel

    21.4. Mexico Ocular Drug Delivery Systems Market Analysis

        21.4.1. By Technology

        21.4.2. By Dosage Form

        21.4.3. By Distribution Channel

    21.5. Brazil Ocular Drug Delivery Systems Market Analysis

        21.5.1. By Technology 

        21.5.2. By Dosage Form

        21.5.3. By Distribution Channel

    21.6. U.K. Ocular Drug Delivery Systems Market Analysis

        21.6.1. By Technology

        21.6.2. By Dosage Form

        21.6.3. By Distribution Channel

    21.7. Germany Ocular Drug Delivery Systems Market Analysis

        21.7.1. By Technology

        21.7.2. By Dosage Form

        21.7.3. By Distribution Channel

    21.8. France Ocular Drug Delivery Systems Market Analysis

        21.8.1. By Technology

        21.8.2. By Dosage Form

        21.8.3. By Distribution Channel

    21.9. Italy Ocular Drug Delivery Systems Market Analysis

        21.9.1. By Technology

        21.9.2. By Dosage Form

        21.9.3. By Distribution Channel

    21.10. Spain Ocular Drug Delivery Systems Market Analysis

        21.10.1. By Technology

        21.10.2. By Dosage Form

        21.10.3. By Distribution Channel

    21.11. BENELUX Ocular Drug Delivery Systems Market Analysis

        21.11.1. By Technology

        21.11.2. By Dosage Form

        21.11.3. By Distribution Channel

    21.12. Russia Ocular Drug Delivery Systems Market Analysis

        21.12.1. By Technology

        21.12.2. By Dosage Form

        21.12.3. By Distribution Channel

    21.13. China Ocular Drug Delivery Systems Market Analysis

        21.13.1. By Technology

        21.13.2. By Dosage Form

        21.13.3. By Distribution Channel

    21.14. Japan Ocular Drug Delivery Systems Market Analysis

        21.14.1. By Technology

        21.14.2. By Dosage Form

        21.14.3. By Distribution Channel

    21.15. South Korea Ocular Drug Delivery Systems Market Analysis

        21.15.1. By Technology

        21.15.2. By Dosage Form

        21.15.3. By Distribution Channel

    21.16. India Ocular Drug Delivery Systems Market Analysis

        21.16.1. By Technology

        21.16.2. By Dosage Form

        21.16.3. By Distribution Channel

    21.17. ASEAN Ocular Drug Delivery Systems Market Analysis

        21.17.1. By Technology

        21.17.2. By Dosage Form

        21.17.3. By Distribution Channel

    21.18. Australia Ocular Drug Delivery Systems Market Analysis

        21.18.1. By Technology

        21.18.2. By Dosage Form

        21.18.3. By Distribution Channel

    21.19. New Zealand Ocular Drug Delivery Systems Market Analysis

        21.19.1. By Technology

        21.19.2. By Dosage Form

        21.19.3. By Distribution Channel

    21.20. GCC Countries Ocular Drug Delivery Systems Market Analysis

        21.20.1. By Technology

        21.20.2. By Dosage Form

        21.20.3. By Distribution Channel

    21.21. Turkey Ocular Drug Delivery Systems Market Analysis

        21.21.1. By Technology

        21.21.2. By Dosage Form

        21.21.3. By Distribution Channel

    21.22. South Africa Ocular Drug Delivery Systems Market Analysis

        21.22.1. By Technology

        21.22.2. By Dosage Form

        21.22.3. By Distribution Channel

22. Market Structure Analysis

    22.1. Market Analysis by Tier of Companies

    22.2. Market Concentration

    22.3. Market Share Analysis of Top Players

    22.4. Market Presence Analysis

        22.4.1. By Regional Foot Print of Players

        22.4.2. Product Foot Print by Players

        22.4.3. Channel Foot Print by Players

23. Competition Analysis

    23.1. Competition Dashboard

    23.2. Competition Benchmarking

    23.3. Competition Deep Dive

        23.3.1. Allergan Plc.

            23.3.1.1. Overview

            23.3.1.2. Product Portfolio

            23.3.1.3. Analyst Commentary

            23.3.1.4. Key Financials

            23.3.1.5. Recent Developments

            23.3.1.6. Sales Footprint

            23.3.1.7. Strategy Overview

                23.3.1.7.1. Marketing Strategy

                23.3.1.7.2. Product Strategy

                23.3.1.7.3. Channel Strategy

        23.3.2. Graybug Vision Inc.

            23.3.2.1. Overview

            23.3.2.2. Product Portfolio

            23.3.2.3. Analyst Commentary 

            23.3.2.4. Key Financials

            23.3.2.5. Recent Developments

            23.3.2.6. Sales Footprint

            23.3.2.7. Strategy Overview

                23.3.2.7.1. Marketing Strategy

                23.3.2.7.2. Product Strategy

                23.3.2.7.3. Channel Strategy

        23.3.3. Ocular Therapeutix, Inc.

            23.3.3.1. Overview

            23.3.3.2. Product Portfolio

            23.3.3.3. Analyst Commentary 

            23.3.3.4. Key Financials

            23.3.3.5. Recent Developments

            23.3.3.6. Sales Footprint

            23.3.3.7. Strategy Overview

                23.3.3.7.1. Marketing Strategy

                23.3.3.7.2. Product Strategy

                23.3.3.7.3. Channel Strategy

        23.3.4. Alimera Sciences

            23.3.4.1. Overview

            23.3.4.2. Product Portfolio

            23.3.4.3. Analyst Commentary 

            23.3.4.4. Key Financials

            23.3.4.5. Recent Developments

            23.3.4.6. Sales Footprint

            23.3.4.7. Strategy Overview

                23.3.4.7.1. Marketing Strategy

                23.3.4.7.2. Product Strategy

                23.3.4.7.3. Channel Strategy

        23.3.5. pSivida

            23.3.5.1. Overview

            23.3.5.2. Product Portfolio

            23.3.5.3. Analyst Commentary 

            23.3.5.4. Key Financials

            23.3.5.5. Recent Developments

            23.3.5.6. Sales Footprint

            23.3.5.7. Strategy Overview

                23.3.5.7.1. Marketing Strategy

                23.3.5.7.2. Product Strategy

                23.3.5.7.3. Channel Strategy

        23.3.6. Santen Pharmaceutical Co., Ltd

            23.3.6.1. Overview

            23.3.6.2. Product Portfolio

            23.3.6.3. Analyst Commentary 

            23.3.6.4. Key Financials

            23.3.6.5. Recent Developments

            23.3.6.6. Sales Footprint

            23.3.6.7. Strategy Overview

                23.3.6.7.1. Marketing Strategy

                23.3.6.7.2. Product Strategy

                23.3.6.7.3. Channel Strategy

        23.3.7. Taiwan Liposome Company Ltd.

            23.3.7.1. Overview

            23.3.7.2. Product Portfolio

            23.3.7.3. Analyst Commentary 

            23.3.7.4. Key Financials

            23.3.7.5. Recent Developments

            23.3.7.6. Sales Footprint

            23.3.7.7. Strategy Overview

                23.3.7.7.1. Marketing Strategy

                23.3.7.7.2. Product Strategy

                23.3.7.7.3. Channel Strategy

        23.3.8. Envisia Therapeutics

            23.3.8.1. Overview

            23.3.8.2. Product Portfolio

            23.3.8.3. Analyst Commentary 

            23.3.8.4. Key Financials

            23.3.8.5. Recent Developments

            23.3.8.6. Sales Footprint

            23.3.8.7. Strategy Overview

                23.3.8.7.1. Marketing Strategy

                23.3.8.7.2. Product Strategy

                23.3.8.7.3. Channel Strategy

        23.3.9. Eyegate Pharma

            23.3.9.1. Overview

            23.3.9.2. Product Portfolio

            23.3.9.3. Analyst Commentary 

            23.3.9.4. Key Financials

            23.3.9.5. Recent Developments

            23.3.9.6. Sales Footprint

            23.3.9.7. Strategy Overview

                23.3.9.7.1. Marketing Strategy

                23.3.9.7.2. Product Strategy

                23.3.9.7.3. Channel Strategy

        23.3.10. Valeant Pharmaceuticals International, Inc

            23.3.10.1. Overview

            23.3.10.2. Product Portfolio

            23.3.10.3. Analyst Commentary 

            23.3.10.4. Key Financials

            23.3.10.5. Recent Developments

            23.3.10.6. Sales Footprint

            23.3.10.7. Strategy Overview

                23.3.10.7.1. Marketing Strategy

                23.3.10.7.2. Product Strategy

                23.3.10.7.3. Channel Strategy

        23.3.11. Vision Ophthalmology Group GmbH

            23.3.11.1. Overview

            23.3.11.2. Product Portfolio

            23.3.11.3. Analyst Commentary 

            23.3.11.4. Key Financials

            23.3.11.5. Recent Developments

            23.3.11.6. Sales Footprint

            23.3.11.7. Strategy Overview

                23.3.11.7.1. Marketing Strategy

                23.3.11.7.2. Product Strategy

                23.3.11.7.3. Channel Strategy

        23.3.12. Clearside Biomedical

            23.3.12.1. Overview

            23.3.12.2. Product Portfolio

            23.3.12.3. Analyst Commentary 

            23.3.12.4. Key Financials

            23.3.12.5. Recent Developments

            23.3.12.6. Sales Footprint

            23.3.12.7. Strategy Overview

                23.3.12.7.1. Marketing Strategy

                23.3.12.7.2. Product Strategy

                23.3.12.7.3. Channel Strategy

        23.3.13. URSAPHARM Arzneimittel GmbH

            23.3.13.1. Overview

            23.3.13.2. Product Portfolio

            23.3.13.3. Analyst Commentary 

            23.3.13.4. Key Financials

            23.3.13.5. Recent Developments

            23.3.13.6. Sales Footprint

            23.3.13.7. Strategy Overview

                23.3.13.7.1. Marketing Strategy

                23.3.13.7.2. Product Strategy

                23.3.13.7.3. Channel Strategy

24. Assumptions and Acronyms Used

25. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Ocular Drug Delivery Systems Market Volume (Mn Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 2: Global Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type

Table 3: Global Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 4: Global Ocular Drug Delivery Systems Market Volume (Mn Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 5: Global Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 6: Global Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Region

Table 7: North America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 8: North America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type

Table 9: North America Ocular Drug Delivery Systems Market Volume Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 10: North America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 11: North America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 12: Latin America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 13: Latin America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type

Table 14: Latin America Ocular Drug Delivery Systems Market Volume Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 15: Latin America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 16: Latin America Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 17: Europe Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 18: Europe Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type

Table 19: Europe Ocular Drug Delivery Systems Market Volume Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 20: Europe Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 21: Europe Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 22: South Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 23: South Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type

Table 24: South Asia Ocular Drug Delivery Systems Market Volume Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 25: South Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 26: South Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 27: East Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 28: East Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type

Table 29: East Asia Ocular Drug Delivery Systems Market Volume Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 30: East Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 31: East Asia Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 32: Oceania Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 33: Oceania Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type

Table 34: Oceania Ocular Drug Delivery Systems Market Volume Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 35: Oceania Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 36: Oceania Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 37: MEA Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 38: MEA Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Technology Type

Table 39: MEA Ocular Drug Delivery Systems Market Volume Units) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 40: MEA Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Dosage Form

Table 41: MEA Ocular Drug Delivery Systems Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

Figure 1: Global Ocular Drug Delivery Systems Market Volume Y-o-Y Growth (%), By Dosage Form, 2020–2031

Figure 2: Global Ophthalmic Solution, Price Difference (US$) Per ml, By Region, 2020A

Figure 3: Global Ophthalmic Solution, Price Difference (US$) Per ml, By Region, 2031F

Figure 4: Global Ophthalmic Suspension, Price Difference (US$) Per ml, By Region, 2020A

Figure 5: Global Ophthalmic Suspension, Price Difference (US$) Per ml, By Region, 2031F

Figure 6: Global Ophthalmic Emulsion, Price Difference (US$) Per ml, By Region, 2020A

Figure 7: Global Ophthalmic Emulsion, Price Difference (US$) Per ml, By Region, 2031F

Figure 8: Global Ophthalmic Gels, Price Difference (US$) Per ml By Region, 2020A

Figure 9: Global Ophthalmic Gels, Price Difference (US$) Per ml, By Region, 2031F

Figure 10: Global Ophthalmic Ointments, Price Difference (US$) Per ml, By Region, 2020A

Figure 11: Global Ophthalmic Ointments, Price Difference (US$) Per ml, By Region, 2031F

Figure 12: Global Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2016-2020

Figure 13: Global Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021-2031

Figure 14: Global Ocular Drug Delivery Systems Market Absolute $ Opportunity, 2016-2020

Figure 15: Global Ocular Drug Delivery Systems Market Absolute $ Opportunity, 2021-2031

Figure 16: Global Ocular Drug Delivery Systems Market Share Analysis (%) By Technology Type, 2021 & 2031

Figure 17: Global Ocular Drug Delivery Systems Market Y-o-Y Growth (%) By Technology Type, 2021-2031

Figure 18: Global Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type

Figure 19: Global Ocular Drug Delivery Systems Market Share Analysis (%) By Dosage Form, 2021 & 2031

Figure 20: Global Ocular Drug Delivery Systems Market Y-o-Y Growth (%) By Dosage Form, 2021-2031

Figure 21: Global Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form

Figure 22: Global Ocular Drug Delivery Systems Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 23: Global Ocular Drug Delivery Systems Market Y-o-Y Growth (%) By Distribution Channel, 2021-2031

Figure 24: Global Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel

Figure 25: Global Ocular Drug Delivery Systems Market Share Analysis (%) By Region, 2021 & 2031

Figure 26: Global Ocular Drug Delivery Systems Market Y-o-Y Growth (%) By Region, 2021-2031

Figure 27: Global Ocular Drug Delivery Systems Market Attractiveness Analysis, By Region

Figure 28: North America Ocular Drug Delivery Systems Market Value Share By Technology Type (2021 E)

Figure 29: North America Ocular Drug Delivery Systems Market Value Share By Dosage Form (2021 E)

Figure 30: North America Ocular Drug Delivery Systems Market Value Share By Distribution Channel (2021 E)

Figure 31: North America Ocular Drug Delivery Systems Market Value Share By Country (2021 E)

Figure 32: North America Ocular Drug Delivery Systems Market Value (US$ Mn) Analysis, 2016-2020

Figure 33: North America Ocular Drug Delivery Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2031

Figure 34: North America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type, 2021-2031

Figure 35: North America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form, 2021-2031

Figure 36: North America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel, 2021-2031

Figure 37: North America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Country, 2021-2031

Figure 38: Latin America Ocular Drug Delivery Systems Market Value Share By Technology Type (2021 E)

Figure 39: Latin America Ocular Drug Delivery Systems Market Value Share By Dosage Form (2021 E)

Figure 40: Latin America Ocular Drug Delivery Systems Market Value Share By Distribution Channel (2021 E)

Figure 41: Latin America Ocular Drug Delivery Systems Market Value Share By Country (2021 E)

Figure 42: Latin America Ocular Drug Delivery Systems Market Value (US$ Mn) Analysis, 2016-2020

Figure 43: Latin America Ocular Drug Delivery Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2031

Figure 44: Latin America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type, 2021-2031

Figure 45: Latin America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form, 2021-2031

Figure 46: Latin America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel, 2021-2031

Figure 47: Latin America Ocular Drug Delivery Systems Market Attractiveness Analysis, By Country, 2021-2031

Figure 48: Europe Ocular Drug Delivery Systems Market Value Share By Technology Type (2021 E)

Figure 49: Europe Ocular Drug Delivery Systems Market Value Share By Dosage Form (2021 E)

Figure 50: Europe Ocular Drug Delivery Systems Market Value Share By Distribution Channel (2021 E)

Figure 51: Europe Ocular Drug Delivery Systems Market Value Share By Country (2021 E)

Figure 52: Europe Ocular Drug Delivery Systems Market Value (US$ Mn) Analysis, 2016-2020

Figure 53: Europe Ocular Drug Delivery Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2031

Figure 54: Europe Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type, 2021-2031

Figure 55: Europe Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form , 2021-2031

Figure 56: Europe Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel, 2021-2031

Figure 57: Europe Ocular Drug Delivery Systems Market Attractiveness Analysis, By Country, 2021-2031

Figure 58: South Asia Ocular Drug Delivery Systems Market Value Share By Technology Type (2021 E)

Figure 59: South Asia Ocular Drug Delivery Systems Market Value Share By Dosage Form (2021 E)

Figure 60: South Asia Ocular Drug Delivery Systems Market Value Share By Distribution Channel (2021 E)

Figure 61: South Asia Ocular Drug Delivery Systems Market Value Share By Country (2021 E)

Figure 62: South Asia Ocular Drug Delivery Systems Market Value (US$ Mn) Analysis, 2016-2020

Figure 63: South Asia Ocular Drug Delivery Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2031

Figure 64: South Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type, 2021-2031

Figure 65: South Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form , 2021-2031

Figure 66: South Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel, 2021-2031

Figure 67: South Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Country, 2021-2031

Figure 68: East Asia Ocular Drug Delivery Systems Market Value Share By Technology Type (2021 E)

Figure 69: East Asia Ocular Drug Delivery Systems Market Value Share By Dosage Form (2021 E)

Figure 70: East Asia Ocular Drug Delivery Systems Market Value Share By Distribution Channel (2021 E)

Figure 71: East Asia Ocular Drug Delivery Systems Market Value Share By Country (2021 E)

Figure 72: East Asia Ocular Drug Delivery Systems Market Value (US$ Mn) Analysis, 2016-2020

Figure 73: East Asia Ocular Drug Delivery Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2031

Figure 74: East Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type, 2021-2031

Figure 75: East Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form, 2021-2031

Figure 76: East Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel, 2021-2031

Figure 77: East Asia Ocular Drug Delivery Systems Market Attractiveness Analysis, By Country, 2021-2031

Figure 78: Oceania Ocular Drug Delivery Systems Market Value Share By Technology Type (2021 E)

Figure 79: Oceania Ocular Drug Delivery Systems Market Value Share By Dosage Form (2021 E)

Figure 80: Oceania Ocular Drug Delivery Systems Market Value Share By Distribution Channel (2021 E)

Figure 81: Oceania Ocular Drug Delivery Systems Market Value Share By Country (2021 E)

Figure 82: Oceania Ocular Drug Delivery Systems Market Value (US$ Mn) Analysis, 2016-2020

Figure 83: Oceania Ocular Drug Delivery Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2031

Figure 84: Oceania Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type, 2021-2031

Figure 85: Oceania Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form, 2021-2031

Figure 86: Oceania Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel, 2021-2031

Figure 87: Oceania Ocular Drug Delivery Systems Market Attractiveness Analysis, By Country, 2021-2031

Figure 88: MEA Ocular Drug Delivery Systems Market Value Share By Technology Type (2021 E)

Figure 89: MEA Ocular Drug Delivery Systems Market Value Share By Dosage Form (2021 E)

Figure 90: MEA Ocular Drug Delivery Systems Market Value Share By Distribution Channel (2021 E)

Figure 91: MEA Ocular Drug Delivery Systems Market Value Share By Country (2021 E)

Figure 92: MEA Ocular Drug Delivery Systems Market Value (US$ Mn) Analysis, 2016-2020

Figure 93: MEA Ocular Drug Delivery Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2020-2031

Figure 94: MEA Ocular Drug Delivery Systems Market Attractiveness Analysis, By Technology Type, 2021-2031

Figure 95: MEA Ocular Drug Delivery Systems Market Attractiveness Analysis, By Dosage Form , 2021-2031

Figure 96: MEA Ocular Drug Delivery Systems Market Attractiveness Analysis, By Distribution Channel, 2021-2031

Figure 97: MEA Ocular Drug Delivery Systems Market Attractiveness Analysis, By Country, 2021-2031

Figure 98: U.S. Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 99: U.S. Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 100: U.S. Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 101: U.S. Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 102: Global Vs. U.S. Growth Comparison

Figure 103: Canada Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 104: Canada Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 105: Canada Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 106: Canada Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 107: Global Vs. Canada Growth Comparison

Figure 108: Mexico Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 109: Mexico Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 110: Mexico Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 111: Mexico Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 112: Global Vs. Mexico Growth Comparison

Figure 113: Brazil Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 114: Brazil Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 115: Brazil Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 116: Brazil Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 117: Global Vs. Brazil Growth Comparison

Figure 118: U.K. Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 119: U.K. Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 120: U.K. Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 121: U.K. Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 122: Global Vs. U.K. Growth Comparison

Figure 123: Germany Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 124: Germany Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 125: Germany Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 126: Germany Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 127: Global Vs. Germany Growth Comparison

Figure 128: France Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 129: France Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 130: France Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 131: France Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 132: Global Vs. France Growth Comparison

Figure 133: Italy Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 134: Italy Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 135: Italy Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 136: Italy Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 137: Global Vs. Italy Growth Comparison

Figure 138: Spain Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 139: Spain Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 140: Spain Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 141: Spain Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 142: Global Vs. Spain Growth Comparison

Figure 143: BENELUX Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 144: BENELUX Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 145: BENELUX Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 146: BENELUX Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 147: Global Vs. BENELUX Growth Comparison

Figure 148: Russia Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 149: Russia Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 150: Russia Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 151: Russia Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 152: Global Vs. Russia Growth Comparison

Figure 153: China Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 154: China Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 155: China Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 156: China Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 157: Global Vs. China Growth Comparison

Figure 158: Japan Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 159: Japan Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 160: Japan Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 161: Japan Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 162: Global Vs. Japan Growth Comparison

Figure 163: South Korea Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 164: South Korea Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 165: South Korea Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 166: South Korea Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 167: Global Vs. South Korea Growth Comparison

Figure 168: India Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 169: India Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 170: India Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 171: India Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 172: Global Vs. India Growth Comparison

Figure 173: Malaysia Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 174: Malaysia Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 175: Malaysia Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 176: Malaysia Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 177: Global Vs. Malaysia Growth Comparison

Figure 178: Thailand Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 179: Thailand Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 180: Thailand Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 181: Thailand Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 182: Global Vs. Thailand Growth Comparison

Figure 183: Indonesia Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 184: Indonesia Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 185: Indonesia Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 186: Indonesia Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 187: Global Vs. Indonesia Growth Comparison

Figure 188: Australia Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 189: Australia Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 190: Australia Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 191: Australia Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 192: Global Vs. Australia Growth Comparison

Figure 193: New Zealand Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 194: New Zealand Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 195: New Zealand Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 196: New Zealand Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 197: Global Vs. New Zealand Growth Comparison

Figure 198: Turkey Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 199: Turkey Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 200: Turkey Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 201: Turkey Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 202: Global Vs. Turkey Growth Comparison

Figure 203: GCC Countries Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 204: GCC Countries Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 205: GCC Countries Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 206: GCC Countries Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 207: Global Vs. GCC Countries Growth Comparison

Figure 208: South Africa Ocular Drug Delivery Systems Market Value Analysis (US$ Mn), 2021 & 2031

Figure 209: South Africa Ocular Drug Delivery Systems Market Value Share, By Technology Type, 2021 & 2031

Figure 210: South Africa Ocular Drug Delivery Systems Market Value Share, By Dosage Form, 2021 & 2031

Figure 211: South Africa Ocular Drug Delivery Systems Market Value Share, By Distribution Channel, 2021 & 2031

Figure 212: Global Vs. South Africa Growth Comparison

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Ocular Drug Delivery System Market